Image -
ALP-2402-1,Thomas Kofoed.jpg
– We have been collecting data for eight years, and it is now possible to systematically compare pharmaceuticals in our database with high precision. It’s crucial for quality assurance and efficiency that we can help the client with quality control of their products based on such an extensive databank. It’s likely to transform the way the biopharmaceutical industry looks at impurities, says Thomas Kofoed, co-founder and CEO of Alphalyse. Photo: Alphalyse A/S
go to media item
- License:
- Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
- File format:
- .jpg
- Size:
- 2000 x 3006, 604 KB
